Table 3.

Studies investigating the impact of mid-wall fibrosis on major arrhythmic outcomes in DCM.

Authors	N (MWF)	Inclusion criteria	Arrhythmic end-point	Follow-up (median)	Occurrence of end-point as per presence of MWF
Gulati et al (2013)⁴⁴	472 (142)	Consecutive patients referred for CMR	SCD^* and aborted SCD^† (excluding ATP)	64	Total events 65 Event rate: MWF: 29.6%; no MWF 7.0% HR 5.24 (95% CI 3.15–8.72; p<0.001)
Assomull et al (2006)⁴⁵	101 (35)	Consecutive patients referred for CMR	SCD^* and sustained VT	22	Total events: 7 Event rate: MWF: 14.3%; no MWF 3.3% HR 5.2 (95% CI 1.0–26.9; p=0.03)
Neilan et al (2013)⁴⁶	162 (81)	Consecutive patients referred for CMR	SCD^* and aborted SCD^† (including ATP)	29	Total events: 37 Event rate: MWF: 41.9%; no MWF 3.7% HR 14.0 (95%CI 4.39:45.65; p<0.0001)
Masci et al (2014)⁴⁹	228 (61)	Patients with DCM without a history of HF	Aborted SCD^† (including ATP)	23	Total events: 8 Event rate: MWF: 9.8%; no MWF 1.2% HR 8.31 (95%CI 1.66:41.55; p=0.01)
Perazzolo-Marra et al (2014)⁵⁰	137 (76)	Consecutive patients	SCD^* and aborted SCD^† (including ATP)	36	Total events: 22 Event rate: MWF: 22.3%; no MWF 8.2% HR 4.17 (95% CI 1.56–11.2; p=0.005)
Leyva et al (2012)⁵¹	97 (25)	Patients referred for CRT	SCD^*	35	Total events: 3 Event rate: MWF: 15.0%; no MWF 0% HR 31.0 (95% CI 1.5–627.8; p=0.013)

witnessed cardiac arrest, death within 1 hour after onset of symptoms or unexpected, unwitnessed death in a patient known to have been well 24 hours previously;

^†

sustained VT, resuscitated cardiac arrest, appropriate ICD intervention; ATP – antitachycardia pacing, CI - confidence interval, DCM – dilated cardiomyopathy, HF- heart failure, HR – hazard ratio, PVCs – premature ventricular complexes, OMT – optimal medical therapy; SCD – sudden cardiac death, VT –ventricular tachycardia